Jose Augusto Cardillo

Jose Augusto Cardillo

Auto-generated profile, based on publicly available information

Jose Augusto Cardillo

Hospital de Olhos de Araraquara, Araraquara, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1997 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
DPDante J. Pieramici
Dante J. Pieramici
PSPaul Sternberg
Paul Sternberg
TAThomas M. Aaberg
Thomas M. Aaberg
WBWilliam Z. Bridges
William Z. Bridges
ACAntonio Capone
Antonio Capone
TSTimothy Stout
Timothy Stout

1 May 2006 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
RCRogério A. Costa
Rogério A. Costa
MSMirian Skaf
Mirian Skaf
LMLuiz A.S. Melo
Luiz A.S. Melo
DCDaniela Calucci
Daniela Calucci
JCJose A. Cardillo
Jose A. Cardillo
MWMaciej Wojtkowski
Maciej Wojtkowski

1 June 2011 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
DLDaniel Lavinsky
Daniel Lavinsky
JCJose A. Cardillo
Jose A. Cardillo
LMLuiz A. S. Melo
Luiz A. S. Melo
ADAlessandro Dare
Alessandro Dare
MFMichel E. Farah
Michel E. Farah
RBRubens Belfort
Rubens Belfort
Purpose. To compare modified Early Treatment Diabetic Retinopathy Study (mETDRS) focal/grid laser photocoagulation with normal-density (ND-SDM) or high-density (HD-SDM) subthreshold diode-laser micropulse photocoagulation for the treatment diabetic macular edema (DME). Methods. A prospective, randomized, controlled, double-masked clinical trial with patients with previously untreated DME and best corrected visual acuity (BCVA) worse than 20/40 and better than 20/400. Patients were randomized to receive either mETDRS focal/grid photocoagulation (42 patients), ND-SDM (39 patients), or HD-SDM (42 patients). Before treatment and 1, 3, 6, and 12 months after treatment, all patients underwent ophthalmic examinations, BCVA, color fundus photography, fluorescein angiography, and optical coherence tomography (OCT). Results. At 12 months, the HD-SDM group had the best improvement in BCVA (0.25 logMAR), followed by the mETDRS group (0.08 logMAR), whereas no improvements were seen in the ND-SDM group (0.03 logMAR). All groups showed statistically significant progressive reduction of central macular thickness (CMT) throughout the study (P < 0.001). The HD-SDM group exhibited the greatest CMT reduction (154 μm), which was not significantly different from that of the mETDRS group (126 μm; P = 0.75). Conclusions. At 1 year, the clinical performance of HD-SDM was superior to that of the mETDRS photocoagulation technique, according to the anatomic and functional measures of improvement used in this investigation. A rationale for this treatment modality as a preferable approach is suggested, and the precise role of subthreshold micropulse laser treatment may become more defined as experience grows, guided by optimized treatment guidelines and more comprehensive trials. (Clinicaltrials.gov number, NCT00552435.)

1 February 2007 in Retina
Verified
Journal Article
Closed access
RCRogério A. Costa
Rogério A. Costa
RJRodrigo Jorge
Rodrigo Jorge
DCDaniela Calucci
Daniela Calucci
LMLuiz A. Melo
Luiz A. Melo
JCJosé A. Cardillo
José A. Cardillo
ISIngrid U. Scott
Ingrid U. Scott
To evaluate the safety, visual acuity changes, and morphologic effects associated with intravitreal bevacizumab injections for the management of macular edema due to ischemic central or hemicentral retinal vein occlusion (RVO). In this prospective, open-label study, 7 consecutive patients (7 eyes) with macular edema associated with ischemic central or hemicentral RVO were treated with intravitreal injections of 2.0 mg (0.08 mL) of bevacizumab at 12-week intervals. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 after each injection. Clinical evidence of toxicity and complications as well as changes in logarithm of minimum angle of resolution Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), central macular thickness (CMT) and total macular volume (TMV) shown by optical coherence tomography (OCT), and dye leakage shown by fluorescein angiography were evaluated. The median age of the 7 patients was 65 years (range, 58–74 years), and the median duration of symptoms before injection was 7 months (range, 2.5–16 months). At baseline, mean BCVA was 1.21 (Snellen equivalent, ≈20/320) in the affected eye. Mean baseline CMT and TMV were 730.1 μm and 17.1 mm3, respectively. Fluorescein leakage was observed in the macula and affected retinal quadrants in all seven eyes. Six patients completed the 25-week follow-up examination with reinjections performed at weeks 12 and 24. The most common adverse events were conjunctival hyperemia and subconjunctival hemorrhage at the injection site. At the last follow-up, mean BCVA in the affected eye was 0.68 (Snellen equivalent, 20/100+1). No patient had a decrease in BCVA. Mean CMT and TMV at the 25-week follow-up were 260.3 μm and 9.0 mm3, respectively; fluorescein leakage within the macula and affected retinal quadrants as compared with baseline was markedly reduced in all patients. Coupled with fluorescein angiographic findings, OCT data suggest a trend of macular edema recurrence between 6 weeks and 12 weeks after injection. Intravitreal bevacizumab injections of 2.0 mg at 12-week intervals were well tolerated and were associated with short-term BCVA stabilization or improvement and favorable macular changes in all patients with ischemic RVO and associated macular edema.

1 October 2006 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
RCRoge´rio A. Costa
Roge´rio A. Costa
RJRodrigo Jorge
Rodrigo Jorge
DCDaniela Calucci
Daniela Calucci
JCJose´ A. Cardillo
Jose´ A. Cardillo
LMLuiz A. S. Melo
Luiz A. S. Melo
ISIngrid U. Scott
Ingrid U. Scott
Purpose. To evaluate the safety of three dose regimens of intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) for the management of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).

1 September 2005 in Ophthalmology
Verified
Journal Article
Closed access
JCJosé A. Cardillo
José A. Cardillo
LMLuiz A.S. Melo
Luiz A.S. Melo
RCRogério A. Costa
Rogério A. Costa
MSMirian Skaf
Mirian Skaf
RBRubens Belfort
Rubens Belfort
BKBaruch D. Kuppermann
Baruch D. Kuppermann